NEW YORK (GenomeWeb) – Protea Biosciences has licensed a mass spectrometry-based technology from Yale University aimed at improving diagnosis of melanoma.

The Morgantown, West Virginia-based firm is developing a test that will use proteomic mass spec imaging (MSI), pioneered by Yale Dermatology Professor Rossitza Lazova and Protea's Erin Seeley.

According to the partners, the imaging technology allows researchers to identify hundreds of specific proteins in tissue, which can help distinguish between cancerous melanomas and benign moles, also called melanocytic nevi.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.